NAV-005 / Navrogen - LARVOL DELTA

NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers. (PubMed, BMC Cancer) - "Tumor-produced CA125 impairs therapeutic antibody and ADC efficacy via humoral immunosuppression. NAV-005 counteracts this effect, restoring antitumor activity of antibodies and ADCs in CA125-expressing cancers. These results support the continued development of CA125 antagonists as adjuncts to antibody-based cancer therapies."

Journal • Oncology • FCGR3A • MSLN • MUC16

[VIRTUAL] Development of NAV-005, a humoral immuno-suppressor antagonist for the treatment of CA125-expressing cancers (AACR 2021) - "We have engineered a human IgG1 Fc fusion protein, called NAV-005, that binds to CA125 with high affinity and blocks its binding to SIGLEC receptors and affected antibodies, thus enabling efficient humoral immune mediated tumor cell killing. NAV-005 is being developed as a novel therapeutic agent to treat humoral immuno-suppressed CA125 expressing cancers."

Oncology • MUC16